Please login to the form below

Not currently logged in
Email:
Password:

Amylin and Takeda discontinue obesity drug

Amylin Pharmaceuticals and Takeda Pharmaceutical Company discontinue pramlintide/metreleptin combined obesity treatment following a commercial reassessment

Amylin Pharmaceuticals and Takeda Pharmaceutical Company announced their decision to discontinue the development of pramlintide/metreleptin, a combination therapy for the treatment of obesity. 

This decision was reached after a “commercial reassessment” of the programme. This assessment took into account various factors including a revised development plan and the evolving dynamics within the obesity therapeutic area.

The drug comprised of pramlintide, an analogue of the natural hormone amylin, and metreleptin, an analogue of the natural hormone leptin. At the time of discontinuation, the drug was in its phase II stage, where it was an injection formula taken twice a day. 

Despite the discontinuation, Amylin and Takeda will continue to work together, and will continue to investigate the antibody-related laboratory finding with metreleptin treatment. Neither of the companies are expecting to revise the latest financial guide for their respective 2011 year. 

5th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics